Table 1 Measurements for all outcomes of interest (cognitive and cardiovascular) investigated in the MedLey trial, undertaken at each study time-point
Assessment | 0 months | 3 months | 6 months | Whole sample assessed |
|---|---|---|---|---|
Blood sample | ✓ | ✓ | ✓ | ✓ |
Height | ✓ | ✓ | ||
Weight | ✓ | ✓ | ✓ | ✓ |
Cognitive function/psychological wellbeing | ✓ | ✓ | ✓ | ✓ |
Waist circumference | ✓ | ✓ | ✓ | ✓ |
Blood pressure and heart rate | ✓ | ✓ | ✓ | ✓ |
Body composition and bone mineral density (DEXA) | ✓ | ✓ | ✓ | ✓ |
Blood lipids | ✓ | ✓ | ✓ | ✓ |
hs-CRP | ✓ | ✓ | ✓ | ✓ |
Insulin & glucose | ✓ | ✓ | ✓ | ✓ |
Urinary metabolites | ✓ | ✓ | ✓ | ✓ |
CRTs | ✓ | ✓ | ✓ | ✓ |
PGF2α | ✓ | ✓ | ✓ | ✓ |
RBCFA | ✓ | ✓ | ✓ | ✓ |
FMD | ✓ | ✓ | ✓ | ✓ |
TCD | ✓ | ✓ | ✓ | ✓ |
FFQ | ✓ | ✓ | ✓ | ✓ |
3-day WFR | ✓(2months) | ✓(4 months) | ||
FCI | ✓ | ✓ | Half from cohort 1, all from cohort 2 | |
Telomere length (qPCR) | ✓ | ✓ | 20 males, 20 females | |
Mitochondrial DNA deletions (qPCR) | ✓ | ✓ | 20 males, 20 females | |
DNA base oxidation (qPCR) | ✓ | ✓ | 20 males, 20 females | |
APOε4 genotype | ✓ | ✓ | 20 males, 20 females | |
Plasma oxidised and reduced glutathione | ✓ | ✓ | 20 males, 20 females | |
Micronucleus index (Cytokinesis-block | ✓ | ✓ | 20 males, 20 females | |
micronucleus cytome [CBMNcyt] assay) | ✓ | ✓ | 20 males, 20 females |